Ismail Kola - UCB SA Insider

UCB SA -- USA Stock  

USD 35.08  0.00  0.00%

Chief Scientific Officer, Head of New Medicines Patient Value Unit and Executive VP

Dr. Ismail Kola was Executive Vice President, New Medicines Head and Chief Scientific Officer and Member of the Executive Committee of UCB S.A. since November 2009. He joined the Company in November 2009. He holds a Doctorate in Philosophy in Medicine from the University of Cape Town, South Africa. He also holds a BS from the University of South Africa UNISA and a Bachelors degree from Rhodes University. He joined the Company from Schering Plough Corporationrationration where he was Senior Vice President, Discovery Research and Early Clinical Research Experimental Medicine, ScheringPlough Research Institute, the pharmaceutical research arm of ScheringPlough Corporationrationration, and Chief Scientific Officer, Schering Plough Corporationrationration. He came to ScheringPlough from Merck, where he was Senior Vice President and Site Head, Basic Research. He also chaired Merck Antibacterial and Antifungal Worldwide Business Strategy Team. Prior to that, he was Vice President, Research, and Global Head, Genomics Science and Biotechnology, with Pharmacia Corporationrationration. Prior to his move to Industry, Ismail was Professor of Human Molecular Genetics, Monash University Medical School and Director of the Research Center for Functional Genomics and Human Disease. He was at Monash for approximately 15 years. He holds Adjunct Professorships of Medicine at Washington University, St Louis, Missouri, United States, and Monash University Medical School, Melbourne, Australia a Foreign Adjunct Professorship at The Karolinska Institute, Stockholm, Sweden and is a William Pitt Fellow at Pembroke College, Cambridge University, United Kingdom. He is Member of the Board of Athersys Inc., Biotie Therapies, and Astex Pharmaceuticals.
Age: 59  EVP Since 2009  Ph.D    
32 2 559 99 99  http://www.ucb-group.com
Kola holds a Doctorate in Philosophy in Medicine from the University of Cape Town, South Africa. He also holds a BS from the University of South Africa UNISA and a Bachelors degree from Rhodes University. He joined the Company from Schering Plough Corporationrationrationration where he was Senior Vice President, Discovery Research and Early Clinical Research & Experimental Medicine, ScheringPlough Research Institute, the pharmaceutical research arm of ScheringPlough Corporationrationrationration, and Chief Scientific Officer, Schering Plough Corporationrationrationration. He came to ScheringPlough from Merck, where he was Senior Vice President and Site Head, Basic Research. He also chaired Merck Antibacterial and Antifungal Worldwide Business Strategy Team. Prior to that, he was Vice President, Research, and Global Head, Genomics Science and Biotechnology, with Pharmacia Corporationrationrationration

Ismail Kola Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 5.76 % which means that it generated profit of $5.76 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 13.02 % meaning that it generated $13.02 on every $100 dollars invested by stockholders.
The company has accumulated 1.9 B in total debt with debt to equity ratio (D/E) of 28.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. UCB SA has Current Ratio of 1.09 suggesting that it may not have the ability to pay its financial obligations in time and when they become due.

Similar Executives

Entity Summary

UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. UCB SA (UCBJY) is traded on OTC Market in USA. It is located in Allée de la Recherche, Brussels, and employs 7,643 people.

Did you try this?

Run Price Ceiling Movement Now
   

Price Ceiling Movement

Calculate and plot Price Ceiling Movement for different equity instruments
Hide  View All  Next  Launch Price Ceiling Movement
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add UCB SA to your portfolio

Top Management

UCB SA Leadership Team
Pascale Richetta, President
Detlef Thielgen, CFO
Kay Davies, Director
Anna Richo, EVP
Gerhard Mayr, Chairman
Cyril Janssen, Director
Cedric Rijckevorsel, Director, CFA
JeanChristophe Tellier, Chairman
Arnoud Calesberg, Director
Mark McDade, COO
Xavier Michel, President
Bharat Tewarie, President, MBA
Roch Doliveux, Chairman, Ph.D
Norman Ornstein, Director
Jeff Wren, President
JeanPierre Kinet, Director, Ph.D
Antje Witte, VP
Alice Dautry, Director
Harriet Edelman, Director, MBA
Ulf Wiinberg, Director
Thomas McKillop, Director, Ph.D
Charl Zyl, President
Fabrice Enderlin, President
Pierre Gurdjian, Director
Ismail Kola, EVP, Ph.D
Emmanuel Caeymaex, President
Evelyn Bergendal, Executive
Iris LoewFriedrich, President, Ph.D
CharlesAntoine Janssen, Director
Albrecht Graeve, Director

Stock Performance

UCB SA Performance Indicators